Pfiz­er puts the pres­sure on Eli Lil­ly's JAK in­hibitor Olu­mi­ant with new da­ta in alope­cia area­ta

As Eli Lil­ly looks to se­cure a win for its block­buster Olu­mi­ant in alope­cia area­ta, go­ing where no JAK in­hibitor has gone be­fore, Pfiz­er is com­ing up from be­hind with Phase IIb/III re­sults sug­gest­ing its own can­di­date can help re­grow hair lost due to the au­toim­mune dis­ease.

On Wednes­day, Pfiz­er un­veiled topline re­sults from the AL­LE­GRO tri­al, which en­rolled 718 pa­tients 12 years and old­er with alope­cia area­ta, a con­di­tion that can cause sud­den, se­vere and patchy hair loss. While the pa­tients’ episodes of alope­cia area­ta var­ied in length, they all had one thing in com­mon: They had lost at least half the hair on their scalps.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.